Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 18/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5835444 | 1.00 | GHSR (0.55) | GHSRKCNH2MEN1KMT2AMAPT | |
| SCHEMBL5834819 | 0.88 | GHSR (0.43) | GHSRKCNH2MEN1KMT2AMAPT | |
| SCHEMBL5835590 | 0.88 | GHSR (0.43) | GHSRKCNH2MEN1KMT2AMAPT | |
| SCHEMBL5835630 | 0.88 | GHSR (0.61) | GHSRKCNH2MEN1KMT2AMAPT | |
| SCHEMBL5836507 | 0.88 | GHSR (0.61) | GHSRKCNH2MEN1KMT2AMAPT | |
| SCHEMBL5836161 | 0.79 | GHSR (0.54) | GHSRKCNH2MEN1KMT2AMAPT | |
| SCHEMBL5835783 | 0.79 | GHSR (0.54) | GHSRKCNH2MEN1KMT2AMAPT | |
| SCHEMBL5835658 | 0.77 | GHSR (0.52) | GHSRKCNH2MEN1KMT2AMAPT | |
| SCHEMBL5834794 | 0.77 | GHSR (0.52) | GHSRKCNH2MEN1KMT2AMAPT | |
| SCHEMBL5835271 | 0.77 | GHSR (0.81) | GHSRKCNH2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115767-B2 | Tetraline derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | ABBVIE INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014794-A1 | Tetraline derivatives as ghrelin receptor modulators | GPR119, GHSR, GIPR | GHSR 2/4885KCNH2 3931/4885MEN1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.